Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$11.64+0.17%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Enanta Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	16.25M
EPS	—	-0.405
Annual ending 2027-09-30
Revenue	—	60.42M
EPS	—	-2.198
Annual ending 2028-09-30
Revenue	—	58.85M
EPS	—	-2.668

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve operating income	Management is focused on cutting losses and improving operating income.	Intact	operating income declines or stays flat beyond next 4 quarters	Operating income: $-17.236M FY2026-Q3; GAAP. Published target: operating income improves YoY. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-17,236,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 955cf24f-3f94-4459-a63c-8f76402f0c28. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve positive cash flow from operations	Enanta is working to improve cash flow, reducing negative cash from -$11.7M to -$7.16M.	Broken	cash flow remains negative beyond next 4 quarters	Cash from operations: $-9.972M FY2026-Q3; GAAP. Published target: >= $0 positive cash flow. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-9,972,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q3. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net loss	A primary condition in Enanta Pharmaceuticals, Inc.'s published investment case. The stated target is net loss decreases YoY.	Broken	net loss grows or stays flat beyond next 4 quarters	Net income: $-19.501M FY2026-Q3; GAAP. Published target: net loss decreases YoY. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-19,501,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 955cf24f-3f94-4459-a63c-8f76402f0c28. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance RSV drug trial plans	The company has a promising RSV drug trial that could drive future revenue.	Intact	trial delays or failures reported	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	0
2026-09-01	6	0
2026-10-01	6	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve operating incomeOperating income: $-17.236M
Achieve positive cash flow from operationsPublished status: Broken
Reduce net lossPublished status: Broken
Advance RSV drug trial plansQualitative condition

Next proof point

Nov 16, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-34.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Enanta Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-stage biotechnology business with elevated risk and no current earnings profit. Its long-term thesis is in a watch state: management is advancing key programs, but recent performance is below its industry cohort and confidence has eased to medium.

What's priced into Enanta Pharmaceuticals, Inc.

The valuation evidence is mixed and low confidence: ENTA is described as cheap versus peers, while another valuation measure shows a peer premium. The expectations gap is negative, and pricing is tagged as justified, with no fragility flags; the evidence does not show that optimistic expectations are driving the thesis.

What the fundamentals likely do

Near term, earnings remain hard to read, with an elevated risk of a miss after erratic surprises and a recent earnings miss. Over the multi-year view, management has advanced RSV and immunology trials, but revenue declined and the net loss increased slightly as development continued. Cash and marketable securities fell from $314.7M in 2026-Q1 to $211.5M in 2026-Q3; management says resources and retained royalties should fund operations into fiscal 2029.

What Enanta Pharmaceuticals, Inc. hinges on

The thesis hinges on meeting clinical milestones, including the planned adult RSV trial start in 4Q 2026 and topline data expected in 2027, while advancing the immunology pipeline on schedule. A guidance cut would be a meaningful negative, while continued strength among healthcare bellwethers could support sector momentum. Further weakening in jobs data could raise recession concerns and weigh on cyclical and healthcare names.

Bottom line

Over the next 1 to 3 years, ENTA remains a high-risk development story with active pipeline progress, but ongoing losses, lower cash, and uneven results leave the long-term thesis dependent on execution and clinical progress. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.